Related Experiment Video
Updated: Dec 3, 2025

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Calcification Biomarkers, Subclinical Vascular Disease, and Mortality Among Multiethnic Dialysis Patients
Jessica Fitzpatrick1, Esther D Kim2,3, Stephen M Sozio3,4
1Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada.
Insights
Circulating calcification biomarkers like OPG and FGF23 are modestly linked to cardiovascular disease in hemodialysis patients, but not mortality. Further research in diverse populations is needed.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Biomarker Research
Background:
- Vascular calcification and stiffness are linked to poor outcomes in hemodialysis patients.
- Mechanisms and biomarker associations remain unclear, with conflicting prior studies.
- This study investigates novel calcification biomarkers in incident dialysis patients.
Purpose of the Study:
- To determine associations between circulating calcification biomarkers and cardiovascular disease.
- To examine relationships with vascular calcification, stiffness, and mortality.
- To investigate fibroblast growth factor 23 (FGF23), dp-ucMGP, fetuin-A, and osteoprotegerin (OPG) in hemodialysis.
Main Methods:
- Cross-sectional analysis of 391 incident hemodialysis participants from the PACE study.
- Assessed baseline FGF23, dp-ucMGP, fetuin-A, and OPG.
- Correlated biomarkers with coronary artery calcium (CAC) score, pulse wave velocity (PWV), and all-cause mortality.
Main Results:
- Higher OPG and FGF23 associated with increased coronary artery calcium prevalence.
- OPG linked to higher baseline PWV; FGF23 linked to lower PWV over time.
- dp-ucMGP and fetuin-A showed no association with CAC or PWV.
- No circulating biomarkers were associated with mortality after adjustment.
Conclusions:
- Circulating calcification biomarkers show modest associations with subclinical cardiovascular disease in hemodialysis.
- No biomarkers were significantly associated with mortality in this cohort.
- Further validation in larger, diverse hemodialysis populations is warranted.
Introduction:
Vascular calcification and stiffness are associated with higher mortality and cardiovascular disease in hemodialysis patients, but the underlying mechanism is not well elucidated and previous studies have been contradictory. We sought to determine the association of circulating calcification biomarkers with calcification, stiffness, and mortality in a multiethnic incident dialysis population.
Methods:
Among 391 incident hemodialysis participants enrolled in the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study, we examined the cross-sectional associations of baseline fibroblast growth factor 23 (FGF23), desphospho-uncarboxylated matrix Gla protein (dp-ucMGP), fetuin-A, and osteoprotegerin (OPG) according to total coronary artery calcium score (CAC, using the Agatston calcification criteria) at baseline, vascular stiffness (pulse wave velocity [PWV]) over 4 study visits, and all-cause mortality.
Results:
Patients' mean age was 55 years; 40% were female, 72% were African American, and 58% had diabetes. Higher OPG and FGF23 were associated with a 1.09-fold (per 5-pmol/l increase in OPG; 95% confidence interval [CI]: 1.01-1.17) and 1.12-fold (per increase of 100 log RU/ml in FGF23; 95% CI: 1.02‒1.34) higher prevalence of CAC, independent of demographics, comorbidities, dialysis factors, and serum klotho levels. Higher OPG was associated with higher baseline PWV. Higher FGF23 was associated with lower PWV over follow-up. dp-ucMGP and fetuin-A were not associated with either CAC or vascular stiffness. After adjustment, circulating biomarkers were not associated with mortality risk.
Conclusion:
Several circulating calcification biomarkers were only modestly associated with subclinical cardiovascular disease in an incident multiethnic hemodialysis population; none were associated with mortality. Understanding whether these associations persist in larger, diverse hemodialysis populations is warranted before planning trials.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Hemodialysis III: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention

